DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.
NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data
NeOnc (NASDAQ:NTHI) is heading into its next major catalyst with fresh institutional capital, encouraging Phase 2a data and continued open-market insider buying. The company announced a $15 million registered direct offering priced at-the-market under Nasdaq rules, with new and existing healthcare-focused institutional investors purchasing 3.57 million shares, or pre-funded warrants in lieu of shares, plus warrants covering another 3.57 million shares. The transaction is expected to close around September 10, subject to customary conditions.
An at-the-market registered direct can be substantially more shareholder-friendly than the deeply discounted financings frequently used by small-cap biotech companies. NTHI’s transaction was priced at the market, $4.20, rather than at a headline discount.
NeOnc is raising that capital after a meaningful clinical update. The company reported that its NEO100 Phase 2a study in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma produced 48.9% six-month progression-free survival, versus a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, 86.7% of patients were alive at six months, and five of 24 patients remained on treatment.
NeOnc plans to request a Type B meeting with the FDA to discuss a potential registrational pathway for NEO100, an intranasal formulation of purified perillyl alcohol designed to address challenges associated with CNS drug delivery. The company is also developing NEO212, which completed Phase 1 and established a recommended Phase 2 dose of 610 mg. Meanwhile, insiders have continued buying: CEO Amir Heshmatpour reported additional purchases in August, while director Thomas Chen, M.D., Ph.D., reported buying 33,787 shares at $3.8477 on August 14 and 2,472 shares at $4.0445 on August 17.
Opus Genetics Delivers BEST1 Data and Suddenly Phase 3 is on the Radar
Opus Genetics (NASDAQ:IRD) delivered an important clinical update from its OPGx-BEST1 gene-therapy program, reporting positive three- and six-month results from the first cohort of the BIRD-1 Phase 1/2 trial. All five participants demonstrated clinically meaningful improvement in at least one measure of visual function, while structural improvements were observed in four participants. BCVA improved in three of five participants, and retinal sensitivity by microperimetry improved in three of four evaluable participants.
Opus also reported a favorable safety profile; no serious adverse events or dose-limiting toxicities were observed, and the company reported no intraocular inflammation or notable vital-sign or safety-laboratory findings. Structural improvements included reductions in vitelliform material in two of three BVMD patients and reductions in intraretinal fluid in both ARB patients. The company says the strongest functional gains were seen where viable retinal tissue remained, potentially informing future patient selection.
Following an August FDA Type C meeting, Opus said it aligned with the agency on a potential pivotal endpoint involving at least a 3-decibel improvement in microperimetry in prespecified loci combined with a patient-reported outcome. The company expects Phase 3 and commercial manufacturing requirements to be completed in early 2027, with participant dosing in a potential pivotal study expected to begin in 2027.
Meanwhile, Cohort 2 over-enrolled to eight participants and is testing the higher 4.5 × 10⁹ vg/eye dose. Dosing is expected to finish in Q4 2026, with three-month topline data anticipated in Q2 2027. Opus has also said its cash runway is expected to extend into 2029, giving it room to pursue multiple clinical inflection points.
bioAffinity Gets Its Nasdaq Lifeline, Now CyPath Lung Takes Center Stage
bioAffinity Technologies (NASDAQ:BIAF) removed a major listing overhang, as Nasdaq confirmed that the company regained compliance with the exchange’s minimum bid-price requirement and its rights/warrants listing requirement. As a result, BIAF and its warrants, will continue trading on the Nasdaq Capital Market, and the previously scheduled Nasdaq Hearings Panel hearing was canceled.
CEO Maria Zannes called the development significant: “We are pleased to have regained full compliance with Nasdaq’s listing standards.” She added that maintaining the listing allows the company to focus on expanding access to its CyPath Lung test and developing its broader pipeline. The company still has to maintain ongoing compliance with Nasdaq’s requirements.
That shifts attention back to CyPath Lung, bioAffinity’s noninvasive lung-cancer test marketed as a Laboratory Developed Test through subsidiary Precision Pathology Laboratory Services. In published clinical research involving high-risk patients with small indeterminate lung nodules, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value. The company says the test is designed to complement other clinical findings.
Tenon Medical Eliminates a Convertible Note Overhang Before Maturity
Tenon Medical (NASDAQ:TNON) has taken a potentially important balance-sheet step by repaying its outstanding original-issue-discount senior convertible promissory notes in full, ahead of their September 11 maturity date. The notes carried approximately $5.16 million of principal and were issued in March 2026.
The significance is dilution. The notes could be converted into common stock at a price tied to 80% of the VWAP for the three trading days before conversion, subject to the note terms. Tenon therefore had an obligation that could have created additional share issuance at a discount to market prices. Eliminating that liability removes a potential source of dilution and gives the company a cleaner capital structure.
CEO Steven M. Foster described the move as a proactive balance-sheet decision, saying: “By proactively addressing this obligation, we are reducing potential dilution for our shareholders, strengthening our financial position and maintaining greater flexibility to invest in the continued commercialization of our products and expansion of our business.”
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
Media gallery
